Akadeum’s Alerion^TMMicrobubble Cell Separation System: A Case Study in T Cell Banking

Updated on Oct 2, 2024 Share

Akadeum Life Sciences has partnered with a cell therapy Alerion^TM Microbubble Cell Separation System beta customer to help their team develop an improved method for T cell banking. The company faces significant challenges in recovery, purity, and processing time with its existing manual methods, and Akadeum’s Alerion^TM is well suited to overcome the challenges with its proven superior cell recovery, purity, and scalability.

The Challenge

To develop and deliver effective CAR T therapies, the company needed to bank a large number of purified T cells efficiently. Their traditional manual processing method was time-consuming, resulting in suboptimal T cell recovery.

Finding a Solution With Akadeum’s Alerion^TM System

To address these challenges, the company became a beta user of Akadeum’s Alerion^TM Microbubble Cell Separation System. The system, specifically paired with Akadeum’s Human T Cell Leukopak Isolation Kit and the BioRise^T

^M consumable, promised a more efficient process for delivering more T cells faster.

The research team processed three leukopak samples to demonstrate the Alerion^TM’s real-world potential. Flow cytometry measured the percent concentration of TCR+ cells pre- and post-processing, and the results were used to calculate T cell recovery rates.

Figure 1: Consistent, Increased Yield and Superior Purity for T Cell Isolation on the Alerion^TM Microbubble Cell Separation System. 

Discussion

The Alerion^TM Microbubble Cell Separation System  demonstrated substantial improvements for T Cell Isolation:

• Superior purity: As demonstrated in the flow cytometry data, the percentage of TCR+ cells post-processing improved for the beta user. The Alerion^TM Microbubble Cell Separation System consistently enables higher purity T cells for better downstream cell therapy engineering.
• Increased T cell recovery: The Alerion^TM Microbubble Cell Separation System significantly boosted the percentage of T cell recovery. Leukopak samples 1 and 2 processed with the Alerion^TM system achieved T cell recovery rates of 71.3% and 72.4%, respectively. This enables the banking of more T cells for downstream cell therapy applications from a single run.

With Akadeum’s Alerion^TM Microbubble Cell Separation System, the company successfully enhanced its T cell isolation process. The improved recovery rates and reduced processing times allowed them to bank more T cells for their pilot cell therapy trials.

Ready to learn more about how the Alerion^TM Microbubble Cell Separation System can improve your T cell banking and cell therapy workflow? Contact our team today to schedule a demo, or purchase a Human T Cell Leukopak Isolation Kit.